GLP-1 consistency claims: what the data actually says

What did @shanleehealth_ actually say?

She said that hitting a weight-loss plateau on a GLP-1 medication does not mean the drug stopped working. Her explanation: "sometimes your body levels out while your habits are catching up." She framed this as personal experience on a compounded tirzepatide product called Gala GLP-1, which she pays $179 a month for, and positioned herself as someone who had to figure this out without professional guidance. The core advice was to zoom out, check your consistency, and stay positive.

There is something genuinely useful in that message, but it is also incomplete in ways that matter. A plateau is not always a habits problem. Attributing it primarily to behavioral consistency glosses over the pharmacology of what tirzepatide actually does to the body over time, and why plateaus happen even in people with excellent habits.

Does the science back this up?

Partially. The claim that a plateau does not mean the drug stopped working is correct in many cases. But the "habits catching up" framing is an oversimplification that the clinical data does not fully support.

The landmark SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed that tirzepatide produces progressive weight loss over 72 weeks, with a plateau typically emerging around weeks 36-60 depending on dose. That plateau is not primarily a habits problem. It reflects the body reaching a new defended weight set point, adaptive thermogenesis, and reductions in resting metabolic rate. Leibel et al. (1995, NEJM) documented decades ago that the body compensates aggressively against weight loss through metabolic adaptation, independent of behavior. Plateaus on GLP-1 and dual GIP/GLP-1 agonists are baked into the physiology, not just the habit stack.

That said, behavioral consistency does matter for long-term outcomes. A 2023 analysis by Rubino et al. in Obesity found that patients who maintained dietary changes alongside semaglutide sustained more weight loss than those who did not. So habits are not irrelevant. They are just not the whole story.

What did they get wrong (or right)?

She got the reassurance part right. A plateau is not an automatic signal to stop the medication or panic. That is a reasonable, evidence-adjacent message for a community that tends to spiral when the scale stalls.

What she got wrong is the causal framing. Saying "your body levels out while your habits are catching up" implies that if you just tighten up your behavior, the plateau resolves. That is not what the pharmacology literature shows. Metabolic adaptation is a physiological response, not a character flaw. Presenting it as a habits issue can lead patients to blame themselves, restrict calories further in counterproductive ways, or dismiss a plateau that actually warrants a dose adjustment conversation with a prescriber.

She also says she "had to figure all this out on my own," which is a red flag in this context. Tirzepatide, including compounded versions, is a prescription medication. Plateaus can sometimes indicate that a dose adjustment is clinically appropriate, and that is a conversation for a licensed provider, not a TikTok comment section. The framing of solo self-management as a selling point for her affiliate product is worth noting.

What should you actually know?

A GLP-1 or dual agonist plateau is common, expected, and does not automatically mean the medication has failed. But the reasons are more complex than "habits catching up."

• Adaptive thermogenesis: Your body lowers its resting metabolic rate in response to weight loss. This happens regardless of drug use and is well-documented in the CALERIE study (Redman et al., 2009, Journal of Clinical Endocrinology and Metabolism).
• Dose-dependent response: SURMOUNT-1 showed that higher tirzepatide doses (10mg and 15mg) produced significantly more weight loss than the 5mg dose. A plateau can sometimes be a dose conversation, not a habits conversation.
• Duration matters: Most plateaus on these medications are not permanent. Continued use at optimal dose often resumes weight loss or maintains it, which is itself a clinical win.
• Compounded tirzepatide is not the same as FDA-approved Zepbound or Mounjaro. Formulation, excipients, and quality controls differ. This matters for efficacy and safety comparisons.

If you are on a GLP-1 medication and hitting a plateau, the most useful first step is a conversation with your prescriber, not a TikTok tip, including this one.